Post-marketing data reinforce sustained efficacy and safety of Cosentyx in psoriasis

Positive five year efficacy and safety results for Cosentyx (secukinumab) from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis have been released by Swiss pharma giant Novartis (NOVN: VX).

Data will be presented at a key medical congress in the second half of 2017. Five year Phase III data are a recognized milestone for assessing long-term efficacy and safety of innovative treatments.

"Cosentyx has consistently demonstrated sustained efficacy and safety providing psoriasis patients a new standard of long-term care," said Vas Narasimhan, global head of drug development and chief medical officer of Novartis, adding: "With the first data from a pivotal trial with five years of follow up, Cosentyx continues to demonstrate it can provide what psoriasis patients want, a life with clear skin."